Last reviewed · How we verify
Sevelamer Carbonate (GZ419831)
Sevelamer carbonate is a phosphate binder that works by binding to phosphate in the gastrointestinal tract and preventing its absorption into the bloodstream.
Sevelamer carbonate is a phosphate binder that works by binding to phosphate in the gastrointestinal tract and preventing its absorption into the bloodstream. Used for Chronic kidney disease, including hyperphosphatemia.
At a glance
| Generic name | Sevelamer Carbonate (GZ419831) |
|---|---|
| Also known as | Renvela |
| Sponsor | Sanofi |
| Drug class | Phosphate binder |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | Phase 3 |
Mechanism of action
This mechanism is thought to be primarily through the formation of insoluble complexes with phosphate, which are then excreted in the feces. Sevelamer carbonate has been shown to be effective in reducing serum phosphate levels in patients with chronic kidney disease.
Approved indications
- Chronic kidney disease, including hyperphosphatemia
Common side effects
- Gastrointestinal upset
- Constipation
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sevelamer Carbonate (GZ419831) CI brief — competitive landscape report
- Sevelamer Carbonate (GZ419831) updates RSS · CI watch RSS
- Sanofi portfolio CI